Concepts in Development

The AGITG research development strategy and prioritisation framework outline the process by which concepts progress from embryonic ideas to funded trials. The concepts listed below have been identified as a research priority for AGITG by the Working Parties, Consumer Advisory Panel and Scientific Advisory Committee, and are currently seeking funds to commence the trial.

If you have any questions related to the information below, please click here.


TUMOUR: Gastro-Oesophageal

To determine the activity of pre- and post-operative chemoimmunotherapy compared with peri-operative chemotherapy plus post-operative immunotherapy in resectable distal oesophageal and GEJ cancer and to validate putative biomarkers for immunotherapy benefit.


TUMOUR: Oesophageal Cancer

Currently oesophageal cancer is the 7th most common cancer and the 6th most common cause of cancer deaths worldwide. Most oesophageal cancers are diagnosed in advanced stages. Today, oesophageal squamous cell carcinoma (SCC) has dismal outcomes worldwide. On a population level only a minority of patients with locally advanced resectable stages survive five years. This study aims to optimise the treatment strategy for patients with oesophageal SCC towards better outcomes in terms of survival, preservation of quality of life and health-economics.

The NEEDS trial will assess whether one of the two tested treatment approaches should be preferred in the future as standard therapy for patients with oesophageal squamous cell carcinoma. The study compares neoadjuvant chemoradiotherapy followed by surgery with definitive chemoradiotherapy, using defined chemoradiotherapy options, with post treatment surveillance and surgery (as needed) to obtain local tumor control.

FOxTROT – 2/3

TUMOUR: Colorectal Cancer

Colon cancer incidence is strongly related to age with its highest incidence in older patients, with 44% of new cases are diagnosed in patients aged 75 or over. Older patients must have access to safe and effective treatments, managing cancer in older adults poses several significant challenges.

FOxTROT-2 aims to investigate whether a modified regime of 6 weeks of chemotherapy prior to surgery and post operation MDT decision regarding Adjuvant Chemotherapy, improves the Disease Free Surivival in older patients with patients with locally advanced operable colon cancer.